KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $10.3 million.

  • Neogenomics' Share-based Compensation changed N/A to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 million, marking a year-over-year increase of 7624.23%. This contributed to the annual value of $33.4 million for FY2024, which is 3564.32% up from last year.
  • Latest data reveals that Neogenomics reported Share-based Compensation of $10.3 million as of Q3 2025.
  • In the past 5 years, Neogenomics' Share-based Compensation registered a high of $12.2 million during Q2 2025, and its lowest value of $2.7 million during Q1 2021.
  • For the 5-year period, Neogenomics' Share-based Compensation averaged around $7.2 million, with its median value being $7.0 million (2023).
  • In the last 5 years, Neogenomics' Share-based Compensation surged by 35620.05% in 2022 and then tumbled by 6068.74% in 2023.
  • Quarter analysis of 5 years shows Neogenomics' Share-based Compensation stood at $10.1 million in 2021, then tumbled by 53.66% to $4.7 million in 2022, then skyrocketed by 49.9% to $7.0 million in 2023, then grew by 19.14% to $8.3 million in 2024, then grew by 23.75% to $10.3 million in 2025.
  • Its Share-based Compensation was $10.3 million in Q3 2025, compared to $12.2 million in Q2 2025 and $10.8 million in Q1 2025.